Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort

Background: Antiphospholipid antibodies (aPLs) have been associated with thrombosis in the antiphospholipid antibody syndrome (APS) and with atherosclerotic vascular events in patients without APS. We examined the significance of aPLs in transient ischemic attack (TIA). Patients/methods: Patients wi...

Full description

Bibliographic Details
Main Authors:	Mullen, Michael T., Messé, Steven R., Kasner, Scott E., Sansing, Lauren, Husain, M. R., Norman, Gary L., Shums, Zakera, Cucchiara, Brett L.
Format:	Online
Language:	English
Published:	Frontiers Research Foundation 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460224/

id	pubmed-3460224
recordtype	oai_dc
spelling	pubmed-34602242012-10-11 Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort Mullen, Michael T. Messé, Steven R. Kasner, Scott E. Sansing, Lauren Husain, M. R. Norman, Gary L. Shums, Zakera Cucchiara, Brett L. Neuroscience Background: Antiphospholipid antibodies (aPLs) have been associated with thrombosis in the antiphospholipid antibody syndrome (APS) and with atherosclerotic vascular events in patients without APS. We examined the significance of aPLs in transient ischemic attack (TIA). Patients/methods: Patients with TIA <48 h from symptom onset were prospectively enrolled. Traditional aPLs, including anticardiolipin and β2-glycoprotein-I (β2GPI), and newer aPLs, including anti-phosphatidylserine/prothrombin (aPS/PT), β2GPI Domain 4/5 and β2GPI Domain 1 were measured. Primary outcome was a composite of stroke or death within 90 days or identification of a high risk stroke mechanism. Secondary outcomes were stroke or death and the presence of clinical/sub-clinical atherosclerosis. Results: Over 4.5 years, 167 patients were enrolled. Forty one patients (25%) had the composite endpoint. Antibodies were measured in 158 subjects. aPS/PT IgG antibodies were significantly associated with stroke/death (OR 16.3, 95% CI 2.3–116.7, p = 0.005) and were non-significantly associated with the composite endpoint (OR 4.7, 95% CI 0.8–29.2, p = 0.10). In multivariate analysis adjusting for ABCD2 risk score, aPS/PT IgG remained associated with stroke/death (OR 15.7, 95% CI 2.0–125.6, p = 0.009). Other aPLs were not associated with clinical outcome and no association between APLs and atherosclerosis was identified. Conclusion: In contrast to other aPLs, aPS/PT IgG antibodies are independently associated with stroke or death in patients with TIA. Frontiers Research Foundation 2012-09-28 /pmc/articles/PMC3460224/ /pubmed/23060855 http://dx.doi.org/10.3389/fneur.2012.00137 Text en Copyright © 2012 Mullen, Messé, Kasner, Sansing, Husain, Norman, Shums and Cucchiara. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Mullen, Michael T. Messé, Steven R. Kasner, Scott E. Sansing, Lauren Husain, M. R. Norman, Gary L. Shums, Zakera Cucchiara, Brett L.
spellingShingle	Mullen, Michael T. Messé, Steven R. Kasner, Scott E. Sansing, Lauren Husain, M. R. Norman, Gary L. Shums, Zakera Cucchiara, Brett L. Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
author_facet	Mullen, Michael T. Messé, Steven R. Kasner, Scott E. Sansing, Lauren Husain, M. R. Norman, Gary L. Shums, Zakera Cucchiara, Brett L.
author_sort	Mullen, Michael T.
title	Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
title_short	Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
title_full	Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
title_fullStr	Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
title_full_unstemmed	Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort
title_sort	anti-phosphatidylserine-prothrombin antibodies are associated with outcome in a tia cohort
description	Background: Antiphospholipid antibodies (aPLs) have been associated with thrombosis in the antiphospholipid antibody syndrome (APS) and with atherosclerotic vascular events in patients without APS. We examined the significance of aPLs in transient ischemic attack (TIA). Patients/methods: Patients with TIA <48 h from symptom onset were prospectively enrolled. Traditional aPLs, including anticardiolipin and β2-glycoprotein-I (β2GPI), and newer aPLs, including anti-phosphatidylserine/prothrombin (aPS/PT), β2GPI Domain 4/5 and β2GPI Domain 1 were measured. Primary outcome was a composite of stroke or death within 90 days or identification of a high risk stroke mechanism. Secondary outcomes were stroke or death and the presence of clinical/sub-clinical atherosclerosis. Results: Over 4.5 years, 167 patients were enrolled. Forty one patients (25%) had the composite endpoint. Antibodies were measured in 158 subjects. aPS/PT IgG antibodies were significantly associated with stroke/death (OR 16.3, 95% CI 2.3–116.7, p = 0.005) and were non-significantly associated with the composite endpoint (OR 4.7, 95% CI 0.8–29.2, p = 0.10). In multivariate analysis adjusting for ABCD2 risk score, aPS/PT IgG remained associated with stroke/death (OR 15.7, 95% CI 2.0–125.6, p = 0.009). Other aPLs were not associated with clinical outcome and no association between APLs and atherosclerosis was identified. Conclusion: In contrast to other aPLs, aPS/PT IgG antibodies are independently associated with stroke or death in patients with TIA.
publisher	Frontiers Research Foundation
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460224/
_version_	1611912565515878400

Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort

Similar Items